Troriluzole

Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD),^[1] obsessive–compulsive disorder (OCD),^[2][3] and glioblastoma.^[4] It is a prodrug formulation of the medication riluzole.^[2][4]

Troriluzole

Clinical data
Other names	Trigriluzole, BHV-4157, FC-4157
Routes of administration	By mouth
ATC code	N07XX23 (WHO)
Identifiers
IUPAC name 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide
CAS Number	1926203-09-9
PubChem CID	121488186
DrugBank	DB15079
ChemSpider	58828005
UNII	S7H48S6K7H
KEGG	D11414
ChEMBL	ChEMBL4297586
Chemical and physical data
Formula	C15H16F3N5O4S
Molar mass	419.38 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN
InChI InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25) Key:YBZSGIWIPOUSHY-UHFFFAOYSA-N

Pharmacology

Pharmacokinetics

While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.^[2][4]

Research

In 2024, researchers published a study in the Journal of Neurochemistry that reported troriluzole could reverse some early Alzheimer's disease brain changes in mice, reduce harmful glutamate levels, and improve memory and learning abilities.^[5][6]